SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Legal Fees
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Legal Fees of $1.91 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LegalFees · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. legal fees for the quarter ending 2026-06-30 was $1.91M, a 254.47% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. legal fees for the quarter ending 2026-03-31 was $789.03K, a 1.10% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. legal fees for the quarter ending 2025-12-31 was $432.83K, a 19.68% increase year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. legal fees for the quarter ending 2025-09-30 was $437.41K, a 66.91% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. legal fees for fiscal 2025 was $2.19M, a 18.46% decline from fiscal 2024.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. legal fees for fiscal 2024 was $2.68M, a 102.09% increase from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. legal fees for fiscal 2023 was $1.33M, a 61.47% increase from fiscal 2022.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. legal fees for fiscal 2022 was $822.73K, a 20.16% increase from fiscal 2021.
| Period end | Legal Fees 3 month | Legal Fees 6 month | Legal Fees 9 month | Legal Fees 12 month | Legal Fees 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.91M 10-Q · filed 2026-09-24 | $2.70M 10-Q · filed 2026-09-24 | $3.13M derived: sum of 3 quarters · filed 2026-09-24 | $3.57M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2026-03-31 | $789.03K 10-Q · filed 2026-05-15 | $1.22M derived: sum of 2 quarters · filed 2026-05-15 | $1.66M derived: sum of 3 quarters · filed 2026-05-15 | $2.20M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-12-31 | $432.83K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $870.24K derived: sum of 2 quarters · filed 2026-03-31 | $1.41M derived: sum of 3 quarters · filed 2026-09-24 | $2.19M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $437.41K 10-Q · filed 2025-11-13 | $975.95K derived: sum of 2 quarters · filed 2026-09-24 | $1.76M 10-Q · filed 2025-11-13 | $2.12M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-06-30 | $538.54K 10-Q · filed 2026-09-24 | $1.32M 10-Q · filed 2026-09-24 | $1.68M derived: sum of 3 quarters · filed 2026-09-24 | $3.00M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-03-31 | $780.43K 10-Q · filed 2026-05-15 | $1.14M derived: sum of 2 quarters · filed 2026-05-15 | $2.46M derived: sum of 3 quarters · filed 2026-05-15 | $2.99M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $361.65K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.68M derived: sum of 2 quarters · filed 2026-03-31 | $2.21M derived: sum of 3 quarters · filed 2026-03-31 | $2.68M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $1.32M 10-Q · filed 2025-11-13 | $1.85M derived: sum of 2 quarters · filed 2025-11-13 | $2.32M 10-Q · filed 2025-11-13 | $2.58M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $526.88K 10-Q · filed 2025-08-13 | $1.00M 10-Q · filed 2025-08-13 | $1.26M derived: sum of 3 quarters · filed 2025-08-13 | $1.55M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $474.13K 10-Q · filed 2025-05-08 | $729.84K derived: sum of 2 quarters · filed 2025-05-08 | $1.02M derived: sum of 3 quarters · filed 2025-05-08 | $1.43M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $255.71K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $544.12K derived: sum of 2 quarters · filed 2025-02-26 | $960.81K derived: sum of 3 quarters · filed 2025-02-26 | $1.33M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $288.42K 10-Q · filed 2024-11-13 | $705.10K derived: sum of 2 quarters · filed 2024-11-13 | $1.07M 10-Q · filed 2024-11-13 | $1.24M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $416.69K 10-Q · filed 2024-09-04 | $784.31K 10-Q · filed 2024-09-04 | $947.08K derived: sum of 3 quarters · filed 2024-09-04 | $1.02M derived: sum of 4 quarters · filed 2024-09-04 | |
| 2023-03-31 | $367.62K 10-Q/A · filed 2024-09-04 | $530.39K derived: sum of 2 quarters · filed 2024-09-04 | $600.96K derived: sum of 3 quarters · filed 2024-09-04 | $861.64K derived: sum of 4 quarters · filed 2024-09-04 | |
| 2022-12-31 | $162.77K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | $233.34K derived: sum of 2 quarters · filed 2024-09-04 | $494.01K derived: sum of 3 quarters · filed 2024-09-04 | $822.73K 10-K/A · filed 2024-09-04 | $866.77K 10-K · filed 2023-03-15 |
| 2022-09-30 | $70.57K 10-Q · filed 2023-11-13 | $331.25K derived: sum of 2 quarters · filed 2023-11-13 | $659.96K 10-Q · filed 2023-11-13 | $1.19M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $260.68K 10-Q · filed 2023-08-14 | $589.39K 10-Q · filed 2023-08-14 | $1.12M derived: sum of 3 quarters · filed 2023-08-14 | $1.17M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $328.71K 10-Q · filed 2023-05-25 | $858.51K derived: sum of 2 quarters · filed 2023-05-25 | $907.25K derived: sum of 3 quarters · filed 2023-05-25 | ||
| 2021-12-31 | $529.80K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $578.53K derived: sum of 2 quarters · filed 2023-03-15 | $684.68K 10-K · filed 2023-03-15 | ||
| 2021-09-30 | $48.74K 10-Q · filed 2022-11-14 | $154.89K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |